A quick peek into the report
Table of Contents
1.1 Market Scope
1.1.1 Key Questions Answered in the Report
1.2 Research Methodology
1.2.1 Acute Care Syndromic Testing Market: Research Methodology
1.2.2 Data Sources
1.2.2.1 Primary Data Sources
1.2.2.2 Secondary Data Sources
1.2.3 Market Estimation Model
1.2.4 Criteria for Company Profiling
2.1 Overview
2.2 Acute Care Syndromic Testing Workflow Analysis
2.3 Market Footprint and Growth Potential
2.4 Future Potential
3.1 Stakeholder’s Perspective (N=20)
3.1.1 Physician’s Perception
3.1.2 Payor’s Perception
3.1.3 Investor’s Perception
3.2 Legal and Regulatory Framework of the Acute Care Syndromic Testing Market
3.2.1 Regulatory Framework in Asia-Pacific
3.2.1.1 Japan
3.2.1.2 China
3.2.1.3 India
3.2.1.4 South Korea
3.2.1.5 Australia
3.3 Product Benchmarking
4.1 Overview
4.2 Impact Analysis
4.3 Market Drivers
4.3.1 Faster Results Acquired with Syndromic Tests
4.3.2 Increasing Incidence of Infectious Diseases
4.3.3 Overall Reduced Cost of Care Due to Early Diagnosis with Syndromic Testing
4.3.4 Reduced Severe Adverse Effects from Pathogens
4.4 Market Challenges
4.4.1 Need for Better Policies with Respect to Acute Care Syndromic Test Reimbursement
4.4.2 Lack of High-Complexity Testing Centres
4.5 Market Opportunities
4.5.1 Quick Access to Treatment and Reduced Use of Antibiotics
4.5.2 High Number of Synergistic Activities and Mergers and Acquisitions (M&A) Over the Past Years
5.1 Overview
5.2 Asia-Pacific
5.2.1 Asia-Pacific Acute Care Syndromic Testing Market, By End User
5.2.2 Asia-Pacific Acute Care Syndromic Testing Market, By Country
5.2.2.1 China
5.2.2.2 Japan
5.2.2.3 India
5.2.2.4 Australia
5.2.2.5 South Korea
5.2.2.6 Rest-of-Asia-Pacific
6.1 Overview
6.2 Acute Care Syndromic Testing Ecosystem Active Players
6.3 Seegene Inc.
6.3.1 Company Overview
6.3.2 Role of Seegene, Inc. in the Acute Care Syndromic Testing Market
6.3.3 Financials
6.3.4 Recent Developments
6.3.4.1 Corporate Strategies
6.3.4.2 Business Strategies
6.3.5 Analyst Perspective
6.4 SpeeDx
6.4.1 Company Overview
6.4.2 Role of SpeeDX in the Acute Care Syndromic Testing Market
6.4.3 Analyst Perspective
6.4.4 Sample Company
6.4.4.1 Overview
6.4.4.2 Top Products / Product Portfolio
6.4.4.3 Top Competitors
6.4.4.4 Target Customers
6.4.4.5 Key Personnel
6.4.4.6 Analyst View
6.4.4.7 Market Share
6.4.5 Sample Company
6.4.5.1 Overview
6.4.5.2 Top Products / Product Portfolio
6.4.5.3 Top Competitors
6.4.5.4 Target Customers
6.4.5.5 Key Personnel
6.4.5.6 Analyst View
6.4.5.7 Market Share
6.4.6 Sample Company
6.4.6.1 Overview
6.4.6.2 Top Products / Product Portfolio
6.4.6.3 Top Competitors
6.4.6.4 Target Customers
6.4.6.5 Key Personnel
6.4.6.6 Analyst View
6.4.6.7 Market Share
6.4.7 Sample Company
6.4.7.1 Overview
6.4.7.2 Top Products / Product Portfolio
6.4.7.3 Top Competitors
6.4.7.4 Target Customers
6.4.7.5 Key Personnel
6.4.7.6 Analyst View
6.4.7.7 Market Share
6.4.8 Sample Company
6.4.8.1 Overview
6.4.8.2 Top Products / Product Portfolio
6.4.8.3 Top Competitors
6.4.8.4 Target Customers
6.4.8.5 Key Personnel
6.4.8.6 Analyst View
6.4.8.7 Market Share
6.4.9 Sample Company
6.4.9.1 Overview
6.4.9.2 Top Products / Product Portfolio
6.4.9.3 Top Competitors
6.4.9.4 Target Customers
6.4.9.5 Key Personnel
6.4.9.6 Analyst View
6.4.9.7 Market Share
Table 1: Acute Care Syndromic Testing Product Mapping Analysis (by Disease Type)
Table 2: Acute Care Syndromic Testing Market: Impact Analysis
Table 3: Key Questions Answered in the Report
Table 4: Product Benchmarking of Acute Care Syndromic Testing Panels
Table 5: Likert Scale
Table 6: Impact Analysis of Market Drivers
Table 7: Impact Analysis of Market Challenges
Table 8: Popular Assays and Their Turnaround Times
Table 9: Acute Care Syndromic Testing Ecosystem Active Players
Figure 1: Asia-Pacific Acute Care Syndromic Testing Market, $Billion, 2023 and 2033
Figure 2: History of Known Pandemics
Figure 3: Share of Acute Care Syndromic Testing Market (by Region), 2022
Figure 4: Share of Key Developments and Strategies, January 2020-June 2023
Figure 5: Acute Care Syndromic Testing Market (by Company), Share (%), 2022
Figure 6: Acute Care Syndromic Testing Market: Research Methodology
Figure 7: Primary Research Methodology
Figure 8: Bottom-Up Approach (Segment-Wise Analysis)
Figure 9: Top-Down Approach (Segment-Wise Analysis)
Figure 10: Acute Care Syndromic Testing Workflow
Figure 11: Asia-Pacific Acute Care Syndromic Testing Market, $Billion, 2022-2033
Figure 12: Physician's Perception on the Factors Affecting the Adoption of Acute Care Syndromic Testing
Figure 13: Acute Care Syndromic Testing Market Dynamics
Figure 14: Traditional Testing vs. Syndromic Testing
Figure 15: Incidence of Common Infectious Diseases in the U.S (Excluding Influenza), 2020
Figure 16: Incidence of Common Infectious Diseases in Germany (Excluding COVID-19), 2020
Figure 17: Incidence of Common Infectious Diseases in China, 2020
Figure 18: History of Known Pandemics
Figure 19: Examples of Cost Reductions
Figure 20: Time of Diagnosis vs. Disease Effect
Figure 21: Syndromic Panels Reimbursement Scenario in the U.S.
Figure 22: Syndromic Panels Reimbursement Scenario in Mexico
Figure 23: Reduction in Antibiotics Use with Syndromic Testing
Figure 24: Increasing Synergistic Activities of the Acute Care Syndromic Testing Market, January 2021-June 2023 (Number of Partnerships, Collaborations and Agreements)
Figure 25: Key Mergers and Acquisitions in the Acute Care Syndromic Testing Market
Figure 26: Acute Care Syndromic Testing Market Snapshot (by Region)
Figure 27: Acute Care Syndromic Testing Market (by Region), $Billion, 2022-2033
Figure 28: Asia-Pacific Acute Care Syndromic Testing Market, $Billion, 2022-2033
Figure 29: Asia-Pacific Acute Care Syndromic Testing Market (by End User), $Billion, 2022-2033
Figure 30: Asia-Pacific Acute Care Syndromic Testing Market (by Country), $Million, 2022-2033
Figure 31: Reported Cases of Top 5 Infectious Diseases, China, 2020
Figure 32: China Acute Care Syndromic Testing Market, $Million, 2022-2033
Figure 33: Japan Acute Care Syndromic Testing Market, $Million, 2022-2033
Figure 34: India Acute Care Syndromic Testing Market, $Million, 2022-2033
Figure 35: Incidence of the Most Common Infectious Diseases in Australia, 2021
Figure 36: Australia Acute Care Syndromic Testing Market, $Million, 2022-2033
Figure 37: South Korea Acute Care Syndromic Testing Market, $Million, 2022-2033
Figure 38: Rest-of-Asia-Pacific Acute Care Syndromic Testing Market, $Million, 2022-2033
Figure 39: Acute Care Syndromic Testing Market, Total Number of Companies Profiled
Figure 40: Seegene, Inc.: Product Portfolio
Figure 41: Seegene, Inc.: Overall Financials, $Million, 2020-2022
Figure 42: Seegene, Inc.: Revenue (by Segment), $Million, 2020-2022
Figure 43: Seegene, Inc.: Revenue (by Region), $Million, 2020-2022
Figure 44: Seegene, Inc.: R&D Expenditure, $Million, 2020-2022
Figure 45: SpeeDX: Product Portfolio
How Can This Report Add Value to an Organization?
Growth/Marketing Strategy: Synergistic activities, product launches, and approvals accounted for the maximum number of key developments.
Competitive Strategy: The APAC acute care syndromic testing market has numerous startups paving their way into manufacturing kits, panels, assays, and instruments and entering the market. Key players in the APAC acute care syndromic testing market analyzed and profiled in the study involve established players that offer various kinds of disease-specific panels and multiplex instruments.
Asia-Pacific Acute Care Syndromic Testing Market Report Coverage:
|
Asia-Pacific Acute Care Syndromic Testing Market |
|||
|
Base Year |
2023 |
Market Size in 2023 |
$0.78 Billion |
|
Forecast Period |
2023-2033 |
Value Projection and Estimation by 2033 |
$2.20 Billion |
|
CAGR During Forecast Period |
10.97% |
|
|
Key Market Players and Competition Synopsis
The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.
Some prominent names established in this market are:
• Seegene Inc.
• SpeeDx
Introduction to Asia-Pacific Acute Care Syndromic Testing Market
The Asia-Pacific acute care syndromic testing market was valued at $0.78 billion in 2023 and is expected to reach $2.20 billion by 2033, growing at a CAGR of 10.97% between 2023 and 2033. The growth of the market can be attributed to the rising need for early detection of infectious diseases, driven by the growing incidence of such diseases, the occurrence of pandemics, and the identification of new infectious diseases in various regions, exacerbated by global warming.
Market Introduction
The Asia-Pacific (APAC) acute care syndromic testing market is experiencing robust growth and increasing prominence in the region's healthcare landscape. Syndromic testing plays a pivotal role in rapidly diagnosing and managing acute illnesses, offering a timely response to outbreaks and emergencies. This market's expansion is driven by factors such as the rising incidence of infectious diseases, growing awareness of the importance of early diagnosis, and advancements in diagnostic technologies.
In recent years, APAC has witnessed significant investments in healthcare infrastructure and the adoption of innovative diagnostic solutions. These investments have bolstered the acute care syndromic testing market, enabling quicker and more accurate diagnoses in emergency and critical care settings. Furthermore, the ongoing COVID-19 pandemic has underscored the critical role of syndromic testing in public health response, further fueling the demand for such testing solutions across the APAC region.
Market Segmentation:
Segmentation 1: by End User
• Hospitals
• Clinical and Diagnostic Laboratories
• Research and Academic Institutions
• Other End Users
Segmentation 2: by Country
• Japan
• India
• China
• South Korea
• Australia
• Rest-of-Asia-Pacific
Asia-Pacific Acute Care Syndromic Testing Market
Analysis and Forecast, 2023-2033
Frequently Asked Questions
This report will be useful for firms planning to enter the acute care syndromic testing market and investors who want to invest in the product. Additionally, established market players in this market can also benefit from this report. This is because the report discusses the benefits of using acute care syndromic testing and the latest advancements in the market right now.
The global acute care syndromic testing market was valued at $3.14 billion in 2022 and is expected to reach $8.44 billion by 2033, growing at a CAGR of 9.43% between 2023 and 2033.
Acute care syndromic testing is commonly used in emergency departments, urgent care centers, and other healthcare settings to rapidly diagnose and manage infectious diseases, identify outbreaks, and make informed treatment decisions for patients with unexplained symptoms.
The integration of advanced technologies enhances the speed and accuracy of syndromic testing. Molecular diagnostics, PCR, and rapid testing methods enable quicker identification of pathogens and syndromes, facilitating timely patient care and outbreak management.
Acute care syndromic testing plays a crucial role in public health by helping detect and monitor the spread of infectious diseases. During epidemics or pandemics, it allows healthcare authorities to track outbreaks, allocate resources efficiently, and implement timely interventions to control the spread of the disease.